Aditxt Inc

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Aditxt Inc's shares fell more than 20% in Tuesday premarket trading after the company announced the pricing of a $6 million private placement of shares and accompanying warrants. The Richmond, Virginia-based medical technologies company said it entered definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock at $4.85 per share and accompanying warrant, in a private placement priced at the market under Nasdaq rules.

Aditxt shares sink on pricing of $6M private placement

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $4.85 per share (or pre-funded warrant in lieu thereof) and accompanying warra.

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Evofem Biosciences Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. KSF is seeking to determine whether the merge.

EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM

Aditxt (NASDAQ: ADTX ) stock is rallying higher on Tuesday after the biotech company announced its plan to acquire Evofem Biosciences (OTCMKTS: EVFM ). According to a press release, Aditxt has agreed to acquire Evofem Biosciences in a deal worth $100 million.

Why Is Aditxt (ADTX) Stock Up 58% Today?

The Aditxt (NASDAQ: ADTX) stock price jumped by more than 83% on Tuesday, making it one of the best performers in Wall Street. The shares surged to a high of $9.47, its highest point since October 19th.

Aditxt (ADTX) stock price just soared but gains could be brief

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aditxt, Inc. (NASDAQ: ADTX) and Evofem Biosciences, Inc. is fair to Aditxt shareholders. Halper Sadeh encourages Aditxt shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Aditxt and its board violated the federa.

ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders

RICHMOND, Va. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women's health, today announced the signing of a definitive agreement (the “Agreement”) under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of c.

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Aditxt (NASDAQ: ADTX ) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why ADTX stock is up today.

Why Is Aditxt (ADTX) Stock Up 70% Today?

Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. (“Pearsanta”). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. T.

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in.

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) and.

Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.

Aditxt stock price has plummeted: avoid at all cost

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrant in lieu thereof) and accompanying warra.

Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Shares of biotechnology firm Aditxt (NASDAQ: ADTX ) — which specializes in therapeutics and technologies that monitor and modulate the immune system — popped up 25% on Friday morning before paring some gains in the early afternoon session. Nevertheless, ADTX stock is still up in double-digit return territory following management's disclosure of its therapeutic portfolio expansion.

Why Is Aditxt (ADTX) Stock Up 10% Today?

RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, is pleased to provide an important update regarding its innovation programs and strategic M&A initiatives. At Aditxt, our DNA is focused on bringing some of the most needed and promising health innovations and solutions to life in a faster, mo.

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

RICHMOND, Va.--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modula.

CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on August 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on August 18, 2023, the Company's common stock will trade on a post-split basis under the.

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an exclusive non-binding Letter of Intent (“LOI”) by Pearsanta,™ Inc. (“Pearsanta”), a wholly-owned subsidiary of Aditxt, to acquire both Natural State Laboratories, LLC (“NSL”) and Natural State Genomics, LLC (“NSG”) (collectively, “Natural State Entities”.

Aditxt, Inc.'s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics

Clover Health Investments

Novo Integrated Sciences, Inc.

OPKO Health

Senseonics Holdings

Spectrum Pharma

Tuya

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1.10 To Watch This Week

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now

RICHMOND, Va.--(BUSINESS WIRE)-- #StiffPersonSyndrome--Aditxt®, Inc. announces that its subsidiary Adimune,™ Inc. has signed a clinical trial agreement with Mayo Clinic to study Stiff Person Syndrome.

Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price.

Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.

News for Aditxt Inc Stock (ADTX)